Cellytics NK – Rapid Immunity Check for All

Cellytics NK is an innovative digital healthcare tool that checks your immune system using advanced technology, Lens-free Imaging Technology. It looks at a special type of immune cell called Natural Killer cells quickly and precisely. These cells are important for your body’s defense. With just a small blood sample, CellyticsTM NK can tell you about your immunity without you having to go to a specific place. The results are given in a simple report that’s easy to understand. This product is a convenient way for anyone to check their immunity in the age of digital health.

 

Link : https://www.ces.tech/ces-innovation-awards/2024/cellyticstm-nk-rapid-immunity-check-for-all/?utm_source=chatgpt.com

Seoul Metropolitan Government hosts the largest-ever ‘Seoul Pavilion’ at CES 2024 with 18 innovation awards recipients

  • Seoul Pavilion at CES 2024: Largest ever, featuring 81 startups across healthcare, AI, mobility, manufacturing, ESG, and quantum tech.

  • Awards: 18 Seoul startups won CES Innovation Awards, including TopTable and LordSystem winning Best of Innovation (top 1%).

  • Mayor Oh Se-hoon: Attended opening, encouraged startups, met award winners, and pledged support to remove regulatory barriers.

  • Partners: 13 institutes (universities, Seoul BioHub, AI Hub, etc.) co-hosted the pavilion.

  • Goal: Expand Seoul’s global smart city competitiveness and help local startups enter international markets.

News Link : https://us.aving.net/news/articleView.html?idxno=50598&utm_source=chatgpt.com

Real-time immune monitoring of immunocompromised patients via lens-free shadow image analysis of natural killer cells

Highlights

  • Cellytics NK with Lens-Free Shadow Imaging enables rapid, accurate, cost-effective real-time assessment of NK cell activity.
  • Novel image-derived biomarkers (PPD, WSM-SD, CSP) and an Innate Immunity Index (I³) distinguish healthy from immunocompromised patients.
  • CSP and I³ show superior prognostic power, with CSP reaching diagnostic accuracy marked by an AUC above 0.95.
  • CSP and I³ outperform conventional hematological markers, including CD107a expression and interferon-γ release, in immune function assessment.
  • Successful commercialization of Cellytics NK highlights its clinical utility and transformative impact in real-world immune monitoring.

News Link : https://www.sciencedirect.com/science/article/abs/pii/S0925400525014224